Astrazeneca
Anglo-Swedish pharma major with a deep oncology and respiratory pipeline.
Coverage of Astrazeneca is holding steady : 4 signals on the latest tracked day, up 33% from its three-week baseline of 3, across 3 domains (up from 2 a week ago). That makes it the #262 most-covered of the 274 concerns we track.
Astrazeneca is steady by its own history. Its normal rhythm is about 3 signals a day across 3 domains (9 tracked days). A real move would be a day at 4+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 3. That is the move that would push it up the Wire.
What’s changed
5 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- ‘No discussions’ ongoing for AstraZeneca-Bristol Myers merger: Reuters · Fierce Pharma · 2026-08-06
- AstraZeneca, CSPC to form joint venture for biologics manufacturing · Fierce Pharma · 2026-08-06
- Why AstraZeneca boss is right to be paranoid about its success · Reddit r/biotech · 2026-08-05
- STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more · STAT News — All Content · 2026-08-04
- Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact · Fierce Biotech · 2026-08-04
- An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled. · BioPharma Dive — Latest News · 2026-08-04
What the reporting says
Across 53 tracked stories from 16 outlets, reporting on Astrazeneca most often describes acquisition (9), regulatory approvals (7), launches or releases (3), IPOs or listings (2), public statements (2), meetings or visits (1).
It shows up alongside Bristol Myers Squibb (26 — acquisition ×3), Merck (15), Pfizer (15), Novartis (11), FDA (11), Eli Lilly (9), Immunotherapy (13), AI (10).
Two steps out: China (through Immunotherapy, 13 shared stories on the weaker link); Colorectal Cancer (through Immunotherapy, 13 shared stories on the weaker link); ctDNA (through Immunotherapy, 13 shared stories on the weaker link); KRAS (through Immunotherapy, 13 shared stories on the weaker link).
Tracked since May 5, with coverage on 23 separate days — concentrated in Preprint and Biotech Pharma.